title: Pharmacological treatment of psychotic agitation.
abstract: The presentation of agitated psychotic patients to psychiatric emergency services is a common occurrence. The traditionally accepted treatment for such patients involves the use of a typical antipsychotic, generally haloperidol. More recently benzodiazepines, such as lorazepam, have been used in combination with antipsychotics due to their sedative properties and relatively benign adverse effect profiles. Standard clinical protocol at many institutions involves the intramuscular administration of 5 to 10mg of haloperidol and 1 to 2mg of lorazepam. Atypical antipsychotics have gained acceptance as first-line treatments for psychotic disorders. These drugs are seen as an improvement over traditional antipsychotics because of their increased efficacy and reduced extrapyramidal effects. The utility of atypical antipsychotics in the emergency setting has been relatively unexplored because slow titration schedules or dose-limiting adverse effects for some members of the class have made this form of treatment impractical. However, the recent availability of oral liquid and rapidly dissolving tablet preparations of some atypical agents has provided useful alternatives in some cases. Nevertheless, for many patients a parenteral drug is the only desirable or feasible treatment option. Intramuscular preparations of the atypical antipsychotics olanzapine and ziprasidone have been developed, and are close to launch in the US. The availability of a rapid-acting intramuscular preparation of an atypical antipsychotic could represent a significant advancement in the treatment of agitation associated with psychosis.
authors.affiliation: Department of Psychiatry, University of Rochester School of Medicine, Rochester, New York 14642, USA. Glenn_Currier@urmc.rochester.edu
authors.forename: Glenn W
authors.initials: GW
authors.lastname: Currier
authors.forename: Adam
authors.initials: A
authors.lastname: Trenton
mesh_terms: D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines; D004637:Emergency Services, Psychiatric / Q000379:methods; D006801:Humans; D011595:Psychomotor Agitation / Q000188:drug therapy* / Q000209:etiology; D011618:Psychotic Disorders / Q000150:complications* / Q000188:drug therapy
chemical_list: D014151:Anti-Anxiety Agents; D014150:Antipsychotic Agents; D001569:Benzodiazepines